10x Genomics (NASDAQ:TXG) Announces Earnings Results, Hits Expectations

10x Genomics (NASDAQ:TXG - Get Free Report) released its earnings results on Tuesday. The company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50), Yahoo Finance reports. The company had revenue of $141.01 million for the quarter, compared to the consensus estimate of $142.24 million. 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. 10x Genomics's revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.44) EPS. 10x Genomics updated its FY 2024 guidance to EPS.

10x Genomics Price Performance

Shares of NASDAQ:TXG opened at $29.28 on Wednesday. 10x Genomics has a 1 year low of $26.30 and a 1 year high of $63.57. The firm has a market capitalization of $3.49 billion, a PE ratio of -13.49 and a beta of 1.90. The business's 50 day moving average price is $36.94 and its 200-day moving average price is $42.40.

Insider Buying and Selling at 10x Genomics

In related news, CEO Serge Saxonov sold 2,821 shares of the business's stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $130,725.14. Following the transaction, the chief executive officer now directly owns 847,560 shares in the company, valued at $39,275,930.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Benjamin J. Hindson sold 2,613 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $121,086.42. Following the completion of the sale, the insider now owns 283,059 shares of the company's stock, valued at approximately $13,116,954.06. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Serge Saxonov sold 2,821 shares of the firm's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $130,725.14. Following the sale, the chief executive officer now directly owns 847,560 shares of the company's stock, valued at approximately $39,275,930.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,959 shares of company stock worth $592,806. Corporate insiders own 10.65% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on TXG. Barclays decreased their target price on 10x Genomics from $55.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, April 10th. Stifel Nicolaus decreased their price objective on shares of 10x Genomics from $68.00 to $63.00 and set a "buy" rating for the company in a research note on Friday, February 16th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of 10x Genomics from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Thursday, April 18th. Finally, Canaccord Genuity Group decreased their target price on shares of 10x Genomics from $65.00 to $50.00 and set a "buy" rating for the company in a research report on Monday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, 10x Genomics currently has a consensus rating of "Moderate Buy" and a consensus price target of $58.00.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.